Phase 2 Data at EULAR Suggested Profervia® Treatment Might Influence Systemic Sclerosis (SSc) Disease Severity BOSTON, June 21, 2023 /PRNewswire/ — Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company today announced initiation of Part 2 of the RECONNOITER Phase 2 study, evaluating Profervia®, a once-daily novel, oral calcium-channel antagonist (CCB) in patients with SSc and Raynaud’s phenomenon(SSc-RP). The study …

AISA Pharma Announces Start of Phase 2b Profervia® Study for Raynaud’s Phenomenon in Systemic Sclerosis (SSc) Read More »

April 3, 2023 – Boston, MA : Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company, announces that the National Institute of Neurological Disorders and Stroke (NINDS)- National Institutes of Health (NIH) have awarded the Preclinical Screening Pain Platform (PSPP) award to Aisa’s Profervia® (cilnidipine), a once-daily novel, investigational, oral calcium-channel antagonist. The PSPP was created …

AISA Pharma Announces NIH-NINDS Award to investigate Profervia® as a non-opioid analgesic for acute and chronic pain Read More »

Profervia® impact on key Nav 1.7 pain channel to be presented at AANInitial Positive Phase 2 data from RECONNOITER-1 Trial in Systemic Sclerosis patients with Raynaud’s Phenomenon to be presented at EULAR April 3, 2023 – Boston, MA : Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company, today announced it will present data on its …

AISA Pharma Announces Upcoming Profervia® Data Presentations at AAN and EULAR Read More »

Company to Move Forward with Key U.S. Regulatory Applications – Investigational New Drug and Orphan Drug Designation BOSTON, July 26, 2022 — Aisa Pharma, Inc. a privately-funded, clinical-stage biopharmaceutical company, today announced that the Data Safety Monitoring Board (DSMB) for the RECONNOITER Phase 2 study of Aisa’s Profervia® once-daily novel, oral calcium-channel antagonist has met …

AISA Pharma Announces Positive Data Safety Monitoring Board Review of First Phase 2 Data of Profervia® to treat Raynaud’s Disease in Scleroderma Patients Read More »

AISA Pharma Announces Initiation of Patient Enrollment in Phase 2 Trial of Novel Therapy for Raynaud’s Disease in Scleroderma June 16, 2021 – Boston, MA : Aisa Pharma, Inc. a privately-funded, clinical-stage biopharmaceutical company, announces that it has begun enrolling patients in a Phase 2 study evaluating the novel investigational therapy Profervia® in patients with …

Aisa Pharma Starts Phase 2 Study of its proprietary drug for Raynauds and Scleroderma Read More »